New hope for breast cancer patients: experimental drug combo enters Mid-Stage trial

NCT ID NCT07666555

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women aged 18 to 75 will take part. The study measures how long the cancer stays under control and how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: culmerciclib (a CDK2/4/6 inhibitor) combined with fulvestrant
What this could lead to: If successful, this could offer a new treatment option for people with HR-positive, HER2-negative breast cancer whose disease has progressed after initial hormone therapy.
What could go wrong: This is a mid-stage trial with only 98 participants, so results may not apply to everyone. The new drug may not be more effective or safer than existing CDK4/6 inhibitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.